Streptomyces albidus mutant strain, construction method and application

By overexpressing the glnR gene in Streptocytica, the mutant strain was constructed, and the fermentation product content and utilization efficiency were solved, and the content of glutenacetin and glutamycin and the antibacterial effect on pathogens was significantly improved. New resources and strategies are provided for the mass production of bacterial antibiotics.

CN118995552APending Publication Date: 2024-11-22GUIZHOU TOBACCO SCI RES INST
View PDF 0 Cites 7 Cited by

Patent Information

Application Number
CN202411225132.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to significantly improve the content of glutenin or glutamycin in the fermentation products of Streptocytica fermentation products, and the utilization efficiency of nitrogen and nitrogen sources and glucose utilization efficiency are low, and the antibacterial effect on certain plant pathogens. Not good.

Method used

By overexpressing the glnR gene in wild-type Streptocytica, mutant strains are constructed, the spore production rate and fermentation product content of the strain are improved, the utilization efficiency of ammonia nitrogen and glucose is enhanced, and the antibacterial effect on certain pathogens is enhanced.

Benefits of technology

The content of glutenin and glutamycin in the fermentation products was significantly improved, the efficiency of the strains in utilization of ammonia nitrogen and glucose was accelerated, and the antibacterial effect on pathogens such as tomato grey mold, apple rot, rice blast, etc. , provides a new strategy for the mass production of antibiotics from bacterial sources.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995552A_ABST
    Figure CN118995552A_ABST
Patent Text Reader

Abstract

The invention discloses a streptomyces albus mutant strain as well as a construction method and application thereof, and belongs to the field of gene engineering. According to the streptomyces albidus mutant strain, a glnR gene is over-expressed in wild streptomyces albidus to obtain the streptomyces albidus mutant strain, the nucleotide sequence of the glnR gene is as shown in SEQ ID NO: 1, and the preservation number of the wild streptomyces albidus is CGMCC No.31251. Experimental verification finds that compared with wild type streptomyces albidus, the streptomyces albidus mutant strain constructed by the invention can significantly improve the content of gougeromycin or toyocamycin in a fermentation product, also can enhance the utilization of glucose in the fermentation product by the strain, and accelerates the utilization efficiency of ammonia nitrogen in the fermentation process by the strain. The invention provides new strain resources and strategies for large-scale production of bacterial-sourced gougeromycin or toyocamycin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of genetic engineering, and in particular to a mutant strain of Streptomyces parvus, a construction method and an application thereof. Background Art

[0002] Microorganisms have strong adaptability and flexibility to the environment, a characteristic that cannot be matched by higher plants and animals. In the long process of evolution, microorganisms have acquired the ability to use a wide range of nitrogen-containing compounds as a source of nitrogen in their own cells. Nitrogen is the main element that constitutes the protein and nucleic acid of organisms. It is one of the necessary conditions for the origin of life and has important biological significance. As one of the most important elements in the survival process of bacteria, the effective absorption and assimilation of nitrogen sources is a challenge that all bacteria will face. In response to this, bacteria will evolve various mechanisms to absorb various nitrogen sources in the environment for their own growth and metabolism.

[0003] The nitrogen metabolism regulation mechanisms of different microorganisms vary greatly, but most microorganisms still have something in common. Their nitrogen metabolism regulation is mediated by a global transcription protein. In many Gram-positive bacteria, GlnR, as a global transcriptional regulatory factor, regulates the expression of its own nitrogen metabolism-related genes. GlnR was first identified in Streptomyces coelicolor. In addition to being able to directly regulate the gene levels of nitrogen source metabolism-related genes such as glnA and amtB, more and more targets have been discovered. Through the study of these targets, it was found that GlnR is deeply involved in the nitrogen source metabolism regulation of Streptomyces coelicolor, including nitrogen source absorption (amtB-glnK-glnD operon), nitrogen source reduction and cleavage (nirB, ureA) and the synthesis of important amino donors glutamate and glutamine (glnA, glnⅡ and gdhA). Among the genes related to the nitrogen metabolism pathway, glnA, gdhA, glnPQ, amtB, nirBD, ureA, glnK, glnD, etc. are all regulated by GlnR. GlnR not only regulates some genes involved in nitrogen metabolism, but also has cross-regulation with secondary metabolic pathways such as phosphate metabolism and antibiotic synthesis. In the cross-regulation of secondary metabolic pathways of antibiotic synthesis, GlnR affects the supply of antibiotic synthesis precursors through nitrogen metabolism pathways on the one hand, and can regulate the biosynthesis of antibiotics through other global regulatory factors or pathway-specific regulatory factors on the other hand. Therefore, it is of great significance to clarify the function of GlnR in Streptomyces albulus CK-15. Summary of the invention

[0004] The purpose of the present invention is to provide a mutant strain of Streptomyces parvum, a construction method and an application thereof, so as to solve the problems existing in the above-mentioned prior art. The mutant strain obtained by overexpressing the glnR gene in the wild-type Streptomyces parvum CK-15 can significantly increase the content of glutamicin or toyocamycin in the fermentation product, thereby providing a new bacterial source and strategy for the large-scale production of bacterial-derived glutamicin or toyocamycin.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] The present invention provides a mutant strain of Streptomyces albulus, which is obtained by overexpressing the glnR gene in a wild-type Streptomyces albulus, wherein the wild-type Streptomyces albulus has a preservation number of CGMCC No. 31251, a preservation time of July 10, 2024, a preservation unit of the General Microbiology Center of the China Culture Collection Administration of Microorganisms, and a preservation address of the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0007] The present invention also provides a method for constructing a mutant strain of Streptomyces parvum, comprising the following steps:

[0008] Cloning the glnR gene, and constructing a recombinant plasmid with the glnR gene and an expression vector; wherein the nucleotide sequence of the glnR gene is shown in SEQ ID NO: 1;

[0009] The recombinant plasmid is transferred to competent Escherichia coli, and then transferred into wild-type Streptomyces parvum by conjugation transfer method to overexpress the glnR gene, thereby obtaining a mutant strain of Streptomyces parvum; the wild-type Streptomyces parvum is deposited with CGMCC No.31251.

[0010] The invention also provides an application of the mutant strain of Streptomyces parvus in producing glutathione.

[0011] The invention also provides an application of the mutant strain of Streptomyces parvum in improving the content of glutathione or toyocamycin in the fermentation product of Streptomyces parvum.

[0012] The present invention also provides an application of the mutant strain of Streptomyces parvum in improving the utilization efficiency of glucose in the fermentation product of Streptomyces parvum.

[0013] The present invention also provides an application of the mutant strain of Streptomyces parvum in improving the utilization efficiency of ammonia nitrogen in the fermentation process of Streptomyces parvum.

[0014] The present invention also provides an application of the mutant strain of Streptomyces parviflorus in inhibiting pathogens, wherein the pathogens include tomato gray mold pathogen (Botrytis cinerea), wheat fusarium rust pathogen (Gibberella sanbinetti), apple rot pathogen (Valsa mail) and rice blast pathogen (Magnaporthe oryzae).

[0015] The present invention also provides a method for producing glutamicin or toyocamycin, which comprises fermenting the mutant strain of Streptomyces parvum and separating and extracting glutamicin or toyocamycin from the fermentation liquid.

[0016] The present invention also provides a method for improving the production of glutathione or toyocamycin by Streptomyces parvum, which comprises overexpressing a glnR gene in a wild-type Streptomyces parvum, and then separating and extracting glutathione or toyocamycin from a fermentation broth through fermentation. The nucleotide sequence of the glnR gene is shown in SEQ ID NO: 1, and the wild-type Streptomyces parvum has a deposit number of CGMCC No. 31251.

[0017] Preferably, the culture medium for fermentation is: soybean cake powder 15.0-25.0 g / L, (NH4)2SO4 3.0-8.0 g / L, glucose 20.0-25.0 g / L, corn flour 25.0-35.0 g / L, CaCO3 1.0-5.0 g / L, and the fermentation conditions are 220 rpm, 28°C for 70-80 h.

[0018] The present invention discloses the following technical effects:

[0019] The present invention constructs a mutant strain of Streptomyces parvum by overexpressing the glnR gene in Streptomyces parvum CK-15. Compared with the wild-type Streptomyces parvum CK-15, the mutant strain of Streptomyces parvum can significantly accelerate the spore production rate of the strain; it can also promote the increase of the content of glutamicin and toyocamycin in the fermentation product, strengthen the strain's utilization of glucose in the fermentation product, and accelerate the strain's utilization efficiency of the ammonia nitrogen source during the fermentation process. In addition, compared with the wild-type Streptomyces parvum CK-15, the mutant strain of Streptomyces parvum has improved antibacterial effects on tomato gray mold pathogens, wheat fusarium rust pathogens, apple rot pathogens, and rice blast pathogens. The present invention transfers the glnR gene into Streptomyces parvum through genetic engineering technology to construct a mutant strain, which can be used to produce glutamicin or toyocamycin, provides new strain resources and methods for large-scale production of glutamicin or toyocamycin from bacteria, and provides new agricultural antibiotic resources and strategies for preventing and controlling various plant diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0021] Figure 1 The electrophoresis results of PCR amplification of glnR gene fragment; M is the standard DNA molecule, glnR is the amplified product;

[0022] Figure 2 The pSETC plasmid electrophoresis results are shown in Figure 1. M is the standard DNA molecule, 1 is the undigested plasmid, and 2 is the digested plasmid.

[0023] Figure 3 This is the growth of single spores after the overexpression recombinant plasmid pSETC-glnR was transferred to CK-15;

[0024] Figure 4 The results of PCR amplification and electrophoresis of the amp fragment of the glnR overexpression conjugate; 1 is the glnR overexpression conjugate, and 2 is CK-15;

[0025] Figure 5 The growth of the oglnR overexpression mutant strain in the plate; the left side of the plate is the CK-15 wild-type strain, and the right side is the oglnR overexpression mutant strain;

[0026] Figure 6 The curves of mycelial dry weight changes at different time periods of CK-15 and the overexpression mutant oglnR;

[0027] Figure 7 Results of determination of glutathione content in fermentation products of CK-15 and overexpression mutant oglnR; A: glutathione standard, B: fermentation product of CK-15 strain, C: fermentation product of overexpression mutant oglnR;

[0028] Figure 8 Results of determination of toyocamycin content in fermentation products of CK-15 and oglnR overexpressing mutant strain; A: toyocamycin standard, B: fermentation product of CK-15 strain, C: fermentation product of oglnR overexpressing mutant strain;

[0029] Fig. 9 The antibacterial effects of CK-15 and the fermentation products of the overexpression mutant oglnR on four pathogens;

[0030] Fig.10 The results of glucose content determination in fermentation products of CK-15 and overexpression mutant oglnR at different time periods;

[0031] Fig.11 The results of ammonia nitrogen content determination in fermentation products of CK-15 and overexpression mutant oglnR at different time periods. DETAILED DESCRIPTION

[0032] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0033] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0034] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0035] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0036] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0037] Example 1 Isolation and Identification of Streptomyces parvum CK-15

[0038] Streptomyces albulus CK-15 was isolated and purified from soil samples collected from Wuyi Mountain area in Fujian Province. Based on routine morphological observations, physiological and biochemical tests, and whole genome sequencing and comparison, it was identified as Streptomyces albulus and named Streptomyces albulus CK-15.

[0039] The Streptomyces albulus CK-15 isolated above was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on July 10, 2024. The deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No.31251.

[0040] Example 2 Construction of overexpression mutants

[0041] 1. Construction of recombinant plasmid pSETC-glnR of overexpression mutant

[0042] The glnR gene fragment was cloned according to the designed primers, and the plasmid pSETC was double-digested with BamH I endonuclease and Spe I endonuclease. The glnR fragment amplification product and the double-digested pSETC plasmid were assembled together by Gibson Assembly one-step isothermal method. After the fragment sequencing was correct, the overexpression recombinant plasmid was obtained and named pSETC-glnR.

[0043] The recombinant plasmid pSETC-glnR was transformed into DH5α by heat shock method, and the single colony was verified as positive by colony PCR and sent to the company for sequencing. The sequencing results fed back by the company were compared with the target gene sequence, and the comparison was consistent. The recombinant plasmid for overexpression of glnR gene was successfully constructed.

[0044] Primers used for cloning:

[0045] glnR-F: 5'-TCAATACTCGATTAGGGATCCAGCCGGCCCGGTTGCGCC-3', (SEQ ID NO: 2);

[0046] glnR-R: 5'-CACGTCTTAAGACGTACTAGTGGCGGAGCACGTCGGCTA-3', (SEQ ID NO: 3).

[0047] The amplification reaction system was: S.albulus CK-15DNA 1 μL, upstream primer (final concentration 10 μM) 2 μL, downstream primer (final concentration 10 μM) 2 μL, 2×PhantaFlash Master Mix 25 μL, and ddH2O was added to a total volume of 50 μL.

[0048] The amplification reaction program was as follows: pre-denaturation at 98°C for 30 s; denaturation at 98°C for 10 s, annealing at 68.5°C for 5 s, extension at 72°C for 7 s, 35 cycles; final extension at 72°C for 1 min, and storage at 4°C.

[0049] The results of electrophoresis detection of amplified products are as follows Figure 1 The results show that the glnR gene fragment (SEQ ID NO: 1) can be successfully amplified and is consistent with the expected results. Figure 2 As shown, the results showed that the enzyme digestion was successful.

[0050] The sequence of glnR gene is: 5'-AGCCGGCCCGGTTGCGCCGCCGCGCCAACTCGTCCTGCGG GTTCTTCCCGATCAACGTCTCACCGGTGTCCACCCGCTCCCCGTGGAGCTGTGACAGCGCGCCCTCCACGTCCCGCCAGACCACCCCGACGGCGATCCCGAAGACGCCCTGGAGCAGATCCACGACCTGGTCGGGCGAGGTGCACTCGTAGACCGTCGCGCCGTCGCTCATCAGCGTCATCCGCGTCAGGTCGTCCAGCCCCCGAGCCCGCAGGTGCTGGACGGCGGTGC GGATGTTCTGCAACGACACCCCGGTGTCCAGCAGCCGCTTGACGATCTTCAGGACGACGACGTCCCGGAAGCTGTAGAGCCGCTGGGTCCCGGACCCGTAGGCCGGCCGGATGCTGGGCTCCACCAGCCCCGTCCGCGCCCAGTAGTCCAGCTGTCGGTAGGTGATGCCCGCCGCCGCGCACGCGGTCGGTCCGCGGTAGCCGACGTGCTCCGCC-3' is a sequence cloned from the genomic fosmid library of Streptomyces albulus CK-15 and is known to be involved in the regulation of nitrogen metabolism.

[0051] 2. Overexpression recombinant plasmid combined with CK-15 strain transfer

[0052] The overexpression recombinant plasmid pSETC-glnR was introduced into ET12567 (pUZ8002) competent cells to obtain ETZ bacterial solution. The overexpression recombinant plasmid introduced into ET12567 (pUZ8002) competent cells was transferred into the CK-15 strain by conjugation transfer. The specific steps of conjugation transfer are as follows:

[0053] (1) The correctly sequenced glnR gene overexpressing ETZ bacterial solution was inoculated into the resistant LB liquid medium and cultured at 37°C, 220 rpm until OD 600Approximately between 0.4-0.6 (close to 0.6).

[0054] (2) Wash fresh spores of CK-15 strain with 2×YT, filter with sterile cotton wool, take 500 μL of the solution and dispense it into 1.5 mL EP tubes. Heat shock at 50°C for 10 min, and pre-germinate at 37°C and 220 rpm for 3 h before use.

[0055] (3) Collect 4-5 mL of ETZ cells in a 1.5 mL EP tube, centrifuge and discard the supernatant in a clean bench. Wash the cells three times with antibiotic-free LB liquid medium and resuspend them in 500 μL antibiotic-free liquid LB for later use.

[0056] (4) After mixing 500 μL of spore suspension with 500 μL of ETZ bacterial solution, centrifuge at 4000 rpm for 5 min, remove 600 μL of supernatant, resuspend the remaining precipitate, take 200 μL and spread it on an MS plate containing MgCl2. After drying, invert and culture at 28°C.

[0057] (5) After 17 hours, observe the plates and apply antibiotics.

[0058] (6) The conjugates will grow after culturing at 28°C for 2-3 days.

[0059] The overexpression recombinant plasmid pSETC-glnR was introduced into the CK-15 wild-type strain by conjugation transfer. Figure 3 As shown, the single colony can still grow normally after being covered with antibiotics, so the plasmid introduction is successful.

[0060] 3. Screening and verification of overexpression mutants

[0061] pSETC is a single-copy integrative plasmid and contains an apramycin resistance gene. Therefore, strains containing the pSETC-glnR recombinant plasmid can grow on MS plates containing apramycin at a final concentration of 50 μg / mL. The strains that can grow on MS plates containing apramycin resistance are purified and cultured, and single colonies are picked for liquid culture, and the genome is extracted for PCR verification. Design of Apra-F / R primers:

[0062] Upstream primer 5′-GAGTGCAATGTCGTGCAATACGA-3′, (SEQ ID NO: 4);

[0063] Downstream primer 5'-GCATTCTTCGCATCCCGCCT-3', (SEQ ID NO: 5).

[0064] If the Apra gene fragment is amplified in the screening strain, it is proved that the strain is a glnR gene overexpression mutant and is named oglnR.

[0065] The glnR overexpression conjugate DNA was extracted and amplified by PCR using primers Apra-F / R and then subjected to agarose gel electrophoresis. Figure 4 It can be seen that the glnR gene overexpression conjugate can amplify the Amp resistance gene fragment (777bp), while the CK-15 wild strain cannot amplify a fragment of the corresponding length. Therefore, the glnR gene overexpression strain oglnR was successfully constructed.

[0066] Example 3 Analysis of culture characteristics of overexpression mutants

[0067] The CK-15 wild-type strain and the overexpression mutant oglnR were streaked into MS medium, cultured at 28°C, and observed every 24 hours for a total of 168 hours.

[0068] The results are as follows Figure 5 As shown, from 72h onwards, the surface of the oglnR mutant strain was covered with gray spores, while the surface of the CK-15 wild-type strain had almost no gray spores. The spore production of the mutant strain was significantly higher than that of the wild-type strain. Therefore, overexpression of the glnR gene can accelerate the spore production rate of the strain.

[0069] Example 4 Overexpression mutant cell growth analysis

[0070] The wild strain of CK-15 and the overexpression mutant oglnR were inoculated into 100mL seed culture medium (glucose 20.0g / L, yeast powder 6.0g / L, NaCl 10.0g / L), and the parameters of the shaker were set to 28℃, 220rpm. The OD value of the seed solution was measured after 1d of culture. 2mL of CK-15 seed solution was added to 100mL M3G medium, and the overexpression strain seed solution was added in the corresponding proportion. Each treatment was repeated three times. Samples were taken every 6h, for a total of 16 times (90h in total). The filter paper dried to a constant weight was first used for filtration, and the filter paper containing the mycelium was placed in an oven at 54℃ for drying to make its weight constant. The difference in weight was the dry weight of the mycelium.

[0071] like Figure 6 As shown, the mycelial dry weight of the oglnR overexpression mutant and the CK-15 wild-type strain was almost consistent throughout the growth cycle, both reaching the maximum value at 42 h. Therefore, the glnR gene had no significant effect on the mycelial growth rate of the strain.

[0072] Example 5 Analysis of hormone production levels in overexpression mutants

[0073] 1. Determination of glutathione content in fermentation products of overexpression mutants

[0074] The wild strain of CK-15 and the bacterial blocks of the overexpressed mutant strain oglnR were inoculated into 100 mL of the above seed culture medium, respectively, and cultured at 220 rpm and 28°C for 24 h. The OD value was measured after the seed solution became turbid. The control group (wild strain) was inoculated into 100 mL of glutathione fermentation medium ((soybean cake powder 20.0 g / L, (NH4)2SO4 4.0 g / L, glucose 20.0 g / L, corn flour 30.0 g / L, CaCO3 3.0 g / L;) at an inoculum of 1%, and the experimental group (mutant strain) was inoculated into the fermentation medium at the same proportion, and cultured at 220 rpm and 28°C for 72 h. The fermentation product was treated with a 0.22 μm bacterial filter, and the content of glutathione in the fermentation product of the strain was detected by HPLC under the following conditions.

[0075] Mobile phase: 1.4 g / L trichloroacetic acid aqueous solution;

[0076] Stationary phase: HPLC grade methanol solution;

[0077] Flow rate: 1.0 mL / min;

[0078] Detection wavelength: 254nm;

[0079] Injection volume: 10 μL;

[0080] Column temperature: 40℃.

[0081] like Figure 7 As shown in the figure, the peak time of glutathione standard is about 8 minutes, and the detection results of CK-15 wild strain and oglnR overexpression mutant strain both have obvious peaks at about 8 minutes, among which the content of glutathione in the fermentation product of CK-15 is 930.96 mg / L, and the content of glutathione in the oglnR mutant strain is 1150.20 mg / L. Compared with the wild strain CK-15, the content of glutathione in the fermentation product of the oglnR mutant strain increased by about 23.55%.

[0082] 2. Determination of Toyocamycin Content in Fermentation Products of Overexpressed Mutant Strain

[0083] The bacterial blocks of CK-15 wild strain and overexpression mutant strain oglnR were inoculated into 100mL of the above seed culture medium, cultured at 220rpm and 28℃ for 24h, and the OD value was measured after the seed solution became turbid. The control group (wild strain) was inoculated into 100mL of Fengjiamycin fermentation medium (glucose 5.0g / L, yeast extract 5.0g / L, beef extract 5.0g / L, corn flour 4.0g / L, soybean cake powder 10.0g / L, starch 20.0g / L, calcium carbonate 4.0g / L) at an inoculum of 1%, and the experimental group (mutant strain) was inoculated into the fermentation medium in proportion, cultured at 220rpm and 28℃ for 72h. The fermentation product was treated with a 0.22μm bacterial filter, and the content of Fengjiamycin in the fermentation product of the strain was detected by HPLC under the following conditions.

[0084] Mobile phase: Milli-Q grade pure water;

[0085] Stationary phase: HPLC grade methanol solution;

[0086] Flow rate: 1.0 mL / min;

[0087] Detection wavelength: 279nm;

[0088] Injection volume: 10 μL;

[0089] Column temperature: 30℃.

[0090] like Figure 8 As shown in the figure, the peak time of the standard product of toyocamycin is about 3.5 minutes, and the detection results of the wild strain of CK-15 and the oglnR overexpression mutant strain both have obvious peaks at about 3.5 minutes. The concentration of toyocamycin in the fermentation product after glnR gene overexpression is 469.84 mg / L, which is 31.71% higher than the toyocamycin content of 356.71 mg / L in the fermentation product of the wild strain of CK-15.

[0091] Example 6 Analysis of antibacterial activity of fermentation products of overexpressed mutants

[0092] Botrytis cinerea, Gibberella sanbinetti, Valsa mail, and Magnaporthe oryzae were selected as target pathogens, and the antibacterial activity of the fermentation products of the wild strain and the overexpression mutant oglnR of CK-15 was determined. The fermentation products of each strain were added to the PDA medium cooled to 37°C and mixed to make the medium contain 1.2% of the fermentation product. After the medium solidified, a sterile punch with a diameter of 0.6 cm was used to take the above pathogen cakes with the same growth conditions, and the side containing the hyphae was placed in the center of the PDA plate with the side facing down. After culturing at 25°C for 3-5 days, the colony growth was observed. PDA without fermentation products was used as the control, and each treatment was repeated 5 times. When the colonies of the control group filled the culture dish, the colony diameter was measured using the cross method, and the antibacterial rate of each treatment group was calculated.

[0093] Inhibition rate = (colony diameter of control group - colony diameter of treatment group) / colony diameter of control group × 100%

[0094] The results are as follows Fig. 9 As shown in Table 1, the fermentation products of the oglnR mutant had control effects of 36.40%, 79.84%, 37.35% and 41.42% on Botrytis cinerea, 79.84% on apple rot, 37.35% on rice blast and 41.42% on wheat fusarium sphaeroides, respectively, which were significantly higher than those of the fermentation products of the wild strain CK-15.

[0095] Table 1 Antibacterial effects of fermentation products of CK-15 and oglnR strains on four pathogenic fungi

[0096]

[0097] Example 7 Determination of glucose content in fermentation products of overexpression mutants

[0098] Take 1 mL of CK-15 wild strain seed liquid and the seed liquid of the overexpression mutant oglnR inoculated into the glutathione fermentation medium in equal volume ratios as the wild strain, and culture at 28°C and 220rpm for 5 days. Sampling was performed every 12 hours for a total of 10 times, and each treatment was repeated 3 times. The glucose content in the fermentation product at different time periods was detected by the glucose content detection kit (Beijing Box Biotechnology). The detection method is as follows:

[0099] (1) Dilute the standard and draw a standard curve.

[0100] Table 2 Preparation of glucose standard curve solution

[0101]

[0102] (2) Preparation of the detection working solution: Mix Reagent 1 and Reagent 2 in the kit in a volume ratio of 1:1. The principle of preparing the working solution before use should be followed.

[0103] (3) Take 20 μL of the fermentation product of each strain at different time periods and add it to a 96-well ELISA plate, then add 180 μL of the detection working solution. For the blank group, replace the fermentation product with distilled water. After thorough mixing, color development was carried out at 37°C for 15 min.

[0104] (4) Measure the absorbance at 505 nm using an ELISA reader.

[0105] (5) Calculate the x value of the sample based on the standard curve and the measured absorbance value.

[0106] (6) Substitute x into the formula: glucose content (μg / mL) = 100 × x × dilution factor to obtain the glucose content of each sample.

[0107] Since there is 2g / 100mL glucose in the fermentation medium of glutathione, the glucose content of each strain fermentation broth is the maximum at 12h. During the fermentation process, the strain will metabolize glucose to produce secondary metabolites. Fig.10 As shown in the figure, with the passage of time, the glucose content in the fermentation broth of the wild strain CK-15 showed a trend of first decreasing, then increasing, and then decreasing again, and the glucose content dropped sharply at 60-72 hours. Compared with the wild strain CK-15, the glucose content in the fermentation broth of the oglnR strain dropped sharply at 72 hours, and it dropped slowly between 12 and 72 hours. Therefore, the glnR gene plays a certain role in the utilization of carbon sources by the strain.

[0108] Example 8 Determination of ammonia nitrogen content in overexpression mutants

[0109] The sodium nitroprusside method was used to determine the ammonia nitrogen content in the fermentation products of the CK-15 wild strain and the overexpression mutant oglnR at different time periods:

[0110] (1) Preparation of the detection working solution: Dissolve 35 g of phenol and 0.2 g of sodium nitrosoferricyanide in distilled water, and dilute to 1 L. Mix well to obtain solution A. Dissolve 18 g of NaOH in distilled water, add 1.8 mL of 0.04 M sodium hypochlorite solution, and dilute to 1 L with distilled water. Mix well to obtain solution B. Solution B is easy to deteriorate and decompose, so it must be prepared before use.

[0111] (2) Take 100 μL of each sample and dilute to 4 mL with distilled water.

[0112] (3) Take 1 mL of each diluted sample into a glass test tube, add 5 mL of solution A and 5 mL of solution B in sequence, mix well and place in a water bath at 37°C for 35 min. Set up 3 replicates for each treatment. Replace the diluted fermentation product with distilled water in the control group.

[0113] (4) Preheat the spectrophotometer for 30 minutes and adjust the wavelength to 625 nm. Use the control group to zero and measure the absorbance of each sample.

[0114] (5) Substitute the measured absorbance value into the formula to determine the ammonia nitrogen value contained in each sample.

[0115] Ammonia nitrogen value = (0.2004 × absorbance value - 0.0018) × sample dilution factor × 0.212

[0116] The sodium nitroprusside method was used to determine the ammonia nitrogen content in the fermentation broth of each strain at different time periods. The results are as follows: Fig.11 As shown in the figure, with the increase of fermentation time, the ammonia nitrogen content in the fermentation broth of each strain showed an overall downward trend. During the entire fermentation process, the ammonia nitrogen content in the fermentation broth of the wild strain CK-15 showed a steady downward trend. After the glnR gene was overexpressed, the ammonia nitrogen content in the fermentation broth of the strain was significantly lower than that of CK-15, and the strain accelerated the utilization of ammonia nitrogen sources.

[0117] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A mutant strain of Streptomyces albulus, characterized in that: The glnR gene is obtained by overexpressing the glnR gene in a wild-type Streptomyces parvum, wherein the wild-type Streptomyces parvum has a preservation number of CGMCC No.31251.

2. A method for constructing a mutant strain of Streptomyces parvum, characterized in that: The following steps are involved: Cloning the glnR gene, and constructing a recombinant plasmid with the glnR gene and an expression vector; wherein the nucleotide sequence of the glnR gene is shown in SEQ ID NO: 1; The recombinant plasmid is transferred to competent Escherichia coli, and then transferred into wild-type Streptomyces parvum by conjugation transfer method to overexpress the glnR gene, thereby obtaining a mutant strain of Streptomyces parvum; the wild-type Streptomyces parvum is deposited with CGMCC No.31251.

3. Use of the mutant strain of Streptomyces parvum as claimed in claim 1 in the production of glutathione.

4. Use of the mutant strain of Streptomyces parvum as claimed in claim 1 for increasing the content of glutathione or toyocamycin in a fermentation product of Streptomyces parvum.

5. Use of the mutant strain of Streptomyces parvum as claimed in claim 1 in improving the glucose utilization efficiency in the fermentation product of Streptomyces parvum.

6. Use of the mutant strain of Streptomyces parvum as claimed in claim 1 in improving the utilization efficiency of ammonia nitrogen in the fermentation process of Streptomyces parvum.

7. Use of the mutant strain of Streptomyces parvum as claimed in claim 1 in inhibiting pathogenic bacteria, characterized in that: The pathogens include tomato gray mold pathogen (Botrytis cinerea), wheat fusarium rust pathogen (Gibberella sanbinetti), apple rot pathogen (Valsa mail) and rice blast pathogen (Magnaporthe oryzae).

8. A method for producing glutathione or toyocamycin, characterized in that: Ferment the mutant strain of Streptomyces parvum according to claim 1, and separate and extract glutathione or toyocamycin from the fermentation broth.

9. A method for increasing the production of glutathione or toyocamycin by Streptomyces parvum, characterized in that: The glnR gene is overexpressed in a wild-type Streptomyces parvum, and then glutathione or toyocamycin is separated and extracted from the fermentation broth through fermentation. The nucleotide sequence of the glnR gene is shown in SEQ ID NO: 1, and the wild-type Streptomyces parvum has a deposit number of CGMCC No.31251.

10. The method according to claim 8 or 9, characterized in that The culture medium for fermentation is: soybean cake powder 15.0-25.0 g / L, (NH4)2SO4 3.0-8.0 g / L, glucose 20.0-25.0 g / L, corn flour 25.0-35.0 g / L, CaCO3 1.0-5.0 g / L, and the fermentation conditions are 220 rpm, 28°C for 70-80 hours.

Citation Information

Cited By

  • Streptomyces albidoflavus mutant strain and application thereof in production of gougerotin

    CN118995513A

  • A mutant strain of Streptomyces parvum and its application in producing glutathione

    CN118995513B

  • Application of streptomyces noursei PUNP1 in production of gougerotin

    CN120330118A

  • Application of Streptomyces noursei PUNP1 in production of gougerotin

    CN120330118B

  • Streptomyces noursei YC3078 and application thereof in production of gougerotin

    CN121780377A